Defence Therapeutics Inc. (DTCFF)
| Market Cap | 27.94M -6.2% |
| Revenue (ttm) | n/a |
| Net Income | -4.33M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 0.3613 |
| Previous Close | 0.3613 |
| Day's Range | 0.3613 - 0.3613 |
| 52-Week Range | 0.2533 - 0.7787 |
| Beta | 1.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 18, 2026 |
About Defence Therapeutics
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X ... [Read more]
News
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Montreal, Quebec--(Newsfile Corp. - August 31, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing n...
IRW-News: Defence Therapeutics Inc.: Defence Therapeutics verstärkt Führungskompetenzen im Radiopharmazeutika …
IRW-PRESS: Defence Therapeutics Inc.: Defence Therapeutics verstärkt Führungskompetenzen im Radiopharmazeutikabereich mit der Ernennung von Dr. Ryan Simms zum Chief Operating Officer und Head of Radi…
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing n...
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
Montreal, Quebec--(Newsfile Corp. - August 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing n...
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing ne...
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracel...
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracell...
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracell...
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracel...
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracell...
Defence Therapeutics Announces Grant of Restricted Stock Units
Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intrac...
Defence Therapeutics Announces Warrant Terms Amendment
Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intrace...
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intrace...
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company advancing next...
Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million
Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intr...
Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board
Montreal, Quebec--(Newsfile Corp. - February 10, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intr...
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intra...
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intra...
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology company, today ann...
Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary in...
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
Montreal, Quebec--(Newsfile Corp. - December 4, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary int...
Defence Therapeutics Announces Convertible Debenture Conversion
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-ge...
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-ge...
Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs
Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-gen...